Your browser doesn't support javascript.
loading
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
Haderski, Gary J; Kandar, Bojidar M; Brackett, Craig M; Toshkov, Ilia M; Johnson, Christopher P; Paszkiewicz, Geraldine M; Natarajan, Venkatesh; Gleiberman, Anatoli S; Gudkov, Andrei V; Burdelya, Lyudmila G.
Afiliación
  • Haderski GJ; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Kandar BM; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Brackett CM; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Toshkov IM; Genome Protection, Inc., Buffalo, New York, United States of America.
  • Johnson CP; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Paszkiewicz GM; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Natarajan V; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Gleiberman AS; Genome Protection, Inc., Buffalo, New York, United States of America.
  • Gudkov AV; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
  • Burdelya LG; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States America.
PLoS One ; 15(2): e0227940, 2020.
Article en En | MEDLINE | ID: mdl-32027657
Tumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the key mediator of cytokine storm and septic shock that can cause severe tissue damage limiting anticancer applications of this cytokine. In our previous studies, we demonstrated that activation of another Toll-like receptor, TLR5, could protect from tissue damage caused by a variety of stresses including radiation, chemotherapy, Fas-activating antibody and ischemia-reperfusion. In this study, we tested whether entolimod could counteract TNF-induced toxicity in mouse models. We found that entolimod pretreatment effectively protects livers and lungs from LPS- and TNF-induced toxicity and prevents mortality caused by combining either of these agents with the sensitizer, D-galactosamine. While LPS and TNF induced significant activation of apoptotic caspase 3/7, lipid tissue peroxidation and serum ALT accumulation in mice without entolimod treatment, these indicators of toxicity were reduced by entolimod pretreatment to the levels of untreated control mice. Entolimod was effective when injected 0.5-48 hours prior to, but not when injected simultaneously or after LPS or TNF. Using chimeric mice with hematopoiesis differing in its TLR5 status from the rest of tissues, we showed that this protective activity was dependent on TLR5 expression by non-hematopoietic cells. Gene expression analysis identified multiple genes upregulated by entolimod in the liver and cultured hepatocytes as possible mediators of its protective activity. Entolimod did not interfere with the antitumor activity of TNF in mouse hepatocellular and colorectal tumor models. These results support further development of TLR5 agonists to increase tissue resistance to cytotoxic cytokines, reduce the risk of septic shock and enable safe systemic application of TNF as an anticancer therapy.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Péptidos / Factor de Necrosis Tumoral alfa / Receptor Toll-Like 5 / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Péptidos / Factor de Necrosis Tumoral alfa / Receptor Toll-Like 5 / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article